Hemophilia doesn’t have a cure, but there are treatments available to help manage hemophilia. What treatment patients receive will depend on the type of hemophilia they have. Adynovate is one of the treatments used to help patients who have hemophilia A.
Patients with hemophilia A either don’t have enough of the clotting factor VIII, or the clotting factor VIII isn’t working properly in them. Adynovate may be able to temporarily replace the missing clotting factor VIII.
Adynovate is made up of the antihemophilic factor, which is a recombinant factor and PEGylated. The medication is injected directly into the patient’s bloodstream to help treat and control bleeding. It can be given to both children and adults as long as they have hemophilia A.
With regular use, Adynovate has been found to reduce the number of bleeding episodes. Adynovate is usually given to patients twice a week.
Patients who are allergic to mice or hamster protein should not use Adynovate.
There is the potential for Adynovate to stop working if the patient’s body forms inhibitors to factor VIII. Doctors can administer blood tests to check and see if inhibitors to factor VIII are developing. It is the body’s normal defense system to form inhibitors, but this may cause problems if the inhibitors begin to affect the effectiveness of Adynovate.
Patients should not administer Adynovate to themselves unless they have been properly instructed by a doctor or healthcare professional to do so. If patients are administering the medication to themselves, they need to ensure that they follow their healthcare professional’s instructions on dosage and schedule. For best results, dosage and schedule of Adynovate must be followed strictly.
Patients should talk to their doctors or to a healthcare professional to find out whether Adynovate is right for them.
Featured image: pressmaster via DepositPhotos
